Only in Titles

           Search results for: Human CA19-9 ELISA ELISA    

paperclip

#28956419   // Save this To Up

Combined detection of tumor markers and serum inflammatory factors in the diagnosis and treatment of gynecologic oncology.

In recent years, gynecologic cancer has become the third leading cause of death for women world-wide. Serum tumor markers and inflammatory factors have been shown to be useful in the diagnosis of gynecological tumors. Therefore, the clinical value of the combined detection of tumor markers and serum inflammatory factors in the diagnosis of gynecologic oncology was studied. One hundred patients with gynecological tumors admitted to our hospital were selected as the tumor group, and 50 healthy volunteers were selected as the control group. According to clinical diagnosis, the tumor group was divided into a malignant tumor group and a benign tumor group. The levels of CA199, CA125, and CEA in each serum were measured by the Elecsys2010 automatic electrochemiluminescence immunoassay system. The levels of serum TNF-α and IL-17 were determined by enzyme-linked immunosorbent assay (ELISA). Our results showed that, when compared with the control group, the levels of CA199, CA125, CEA, TNF-α, and IL-17 in serum of the benign tumor group were significantly increased (P<0.001), and were further increased in the malignant tumor group. Moreover, the positive detection rates of combined detection of CA199, CA125, CEA, TNF-α, and IL-17 for malignant and benign tumors were significantly higher than that of single detection (P<0.05), and the positive detection rate of combined detection of malignant tumors was significantly higher than that of benign tumors (P<0.05). These results indicate that the combined detection of inflammatory factors and tumor markers has a high clinical value in the diagnosis and treatment of gynecological tumors and is worth adopting.

1163 related Products with: Combined detection of tumor markers and serum inflammatory factors in the diagnosis and treatment of gynecologic oncology.

Bovine Androstenedione,AS Multiple organ tumor tiss Sterile filtered goat se Sterile filtered goat se Sterile filtered mouse s Sterile filtered rat ser Human Macrophage Inflamma Human Macrophage Inflamma Human Macrophage Inflamma Human Macrophage Inflamma Human Macrophage Inflamma Human Gro g Macrophage In

Related Pathways

paperclip

#28910954   // Save this To Up

[The value of serum human tumor protein P53 in colorectal cancer combined diagnosis and postoperative monitoring].

The aim of this paper is to investigate the application value of serum human tumor protein P53 (TP53) in the diagnosis and postoperative monitoring of colorectal cancer. One hundred and fifteen patients with colorectal cancer diagnosed without colorectal cancer and without surgery, radiotherapy and chemotherapy and total of 158 patients with colorectal benign disease and 182 healthy subjects were enrolled in this study. The levels of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) were detected by electrochemiluminescence assay. The expression of TP53 was analyzed by ELISA. Fourth-one patients with colorectal cancer were detected with one day before operation and the first seven days after operation. The expression of CEA, CA199 and TP53 was analyzed by ROC curve. The results were compared with those of CEA and CA199 diagnostic value. The medians of the levels of TP53 in patients with colorectal cancer patients, colorectal benign, and healthy subjects are 316.0(24.6, 940.8 ) , 9.8(3.7, 30.1 ) and 1.9(1.4, 2.5 ) μg/L (=260.161, <0.01), respectively. The level of TP53 in patients with colorectal cancer was significantly higher than that in colorectal benign and healthy subjects. The levels of serum TP53 in patients with colorectal cancer show great discrepancies in different TNM stages, different tumor location, depth of invasion and lymph node metastasis (<0.05) , but no difference in sex, age, and tumor growth type. The levels of TP53 in the same patient is 711.5(354.9, 1 068.0) μg/L in the first seven days after operation, significantly decreased when compared to it in the one day before the operation with the value of 952.6 (419.7, 1485.4) μg/L (=-1.989, <0.05). The difference was statistically significant, and CEA, CA199 were not statistically significant. And the sensitivity (79.1%) and specificity (81.8%) of TP 53 were significantly higher than those of CEA (39.1%, 70.3%) and CA199 (47.8%, 69.1%). If TP53 was combined with CEA and CA199, sensitivity (86.1%) and specificity (87.9%) can be significantly improved, in which the area of Receiver Operating Characteristic (ROC) curve was 0.924. Serum TP53 has a certain positive significance for the diagnosis, postoperative monitoring of colorectal cancer. Combined detection with CEA and CA199 can improve the sensitivity and specificity, implicating good clinical application value.

2305 related Products with: [The value of serum human tumor protein P53 in colorectal cancer combined diagnosis and postoperative monitoring].

Human Macrophage Inflamma Human Macrophage Inflamma Human Macrophage Inflamma Human Macrophage Inflamma Human Macrophage Inflamma Human Gro g Macrophage In Breast cancer membrane pr Recombinant Human Inhibin Recombinant Human Inhibin Recombinant Human Intrins Recombinant Human p16-INK Recombinant Human p16-INK

Related Pathways

paperclip

#28638465   // Save this To Up

Prediction of Lymph Node Metastases in Gastric Cancer by Serum APE1 Expression.

To investigate the functional role of serum Human apurinic/apyrimidinic endonuclease 1 (APE1) in prediction of lymph node metastasis in gastric cancer patients. Serum samples were pre-operational collected from 86 patients with gastric cancer from Tianjin Medical University Cancer Institute and Hospital from March 2016 to August 2016. The serum of APE1 was measured by ELISA development kit and other CA242, CA724, CA199 and CEA levels by electrochemiluminescence assay. The total of 86 patients with gastric cancer was classified into two groups (lymph node positive and negative groups). Using ELISA assay, we found out that the concentration of serum APE1 was higher in lymph node positive group than that of lymph node negative group. The receiver operating characteristic (ROC) curve was performed to analyze, indicating that area under the ROC curve of serum APE1 were better than those of each regular markers (CEA+CA199+CA242+CA724) or combination of these markers. Additionally, the APE1 overexpression was uncovered in tissue of gastric cancer patients with lymph nodes metastases, which is correlation with results of serum APE1. Serum APE1 was identified as a valuable marker for prediction of lymph node metastases in patients with gastric cancer.

2900 related Products with: Prediction of Lymph Node Metastases in Gastric Cancer by Serum APE1 Expression.

Colon cancer, metastasize Breast cancer and matched Breast cancer, carcinoma Lung cancer tissue array Small intestine cancer, m Ovary serous papillary ad Breast cancer tissue arra Breast cancer and matched Breast cancer tissue micr Breast fibroadenoma tissu Breast cancer tissue arra Colorectal carcinoma and

Related Pathways

paperclip

#28243980   // Save this To Up

Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3.

Increasing evidence has demonstrated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable progression in patients with malignant tumors. In the present study, we detected sB7-H3 levels in serum to investigate the value of sB7-H3 as a tool for differential diagnosis of cirrhotic patients with or without early-stage hepatocellular carcinoma (ESHCC). We also assessed the diagnostic value of sB7-H3regarding the prediction of overall survival (OS) of cirrhotic patients with ESHCC. sB7-H3 expression was measured in 91 healthy volunteers, 149 cirrhotic patients with ESHCC, and 87 cirrhotic patients by ELISA, and correlations between DCP1a level and clinical characteristics were analyzed. SB7-H3 concentrations were significantly higher in patients with ESHCC than in cirrhotic patients (P < 0.001). Using 48.34 ng/mL as a cutoff value, the sensitivity and specificity of sB7-H3 in differentiating between cirrhotic patients and cirrhotic patients with ESHCC were 76.5 and 93.1%, respectively. Moreover, high serum sB7-H3 in cirrhotic patients with ESHCC correlated with tumor size, tumor stage, vascular invasion, and tumor differentiation. The area under the curve (AUC) value for sB7-H3 (0.898) was significantly higher than those for AFP (0.789), CA199 (0.627), and CA125 (0.545) for differentiating between cirrhotic patients with ESHCC and sex- and age-matched cirrhotic patients without ESHCC. Our data indicate that serum sB7-H3 serves as a valuable biomarker for cirrhotic patients with ESHCC and that high levels of sB7-H3 correlate with poor clinical outcomes.

2165 related Products with: Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3.

Liver hepatocellular carc Liver cancer (hepatocellu Hepatocellular carcinoma Hepatocellular carcinoma Hepatocellular carcinoma Hepatocellular carcinoma Normal liver and hepatoce Syringe pump can be contr Rat TGF-beta-inducible ea Rat TGF-beta-inducible ea rHIV gp36, soluble Antige rHIV gp41, soluble Antige

Related Pathways

paperclip

#26788811   // Save this To Up

Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer.

Human leukocyte antigen-G (HLA-G) is a novel tumor marker. Increased level of soluble HLA-G (sHLA-G) in various tumor types has been reported. However, the potential diagnostic value of sHLA-G with other tumor markers in gastric cancer (GC) diagnosis is yet to be explored. In this study, plasma level of sHLA-G was measured in 81 GC patients, 53 benign gastric disease patients and 77 normal controls by ELISA. The serum levels of alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 19-9 (CA19-9) and cancer antigen 72-4 (CA72-4) were also determined. Data showed that plasma level of sHLA-G in GC was dramatically increased compared with normal controls and benign gastric disease patients (both p<0.001). The AUC for sHLA-G was 0.730 (p<0.001), superior to serum AFP, CEA, CA125, CA19-9 and CA72-4. After evaluating three cut-offs of sHLA-G, we concluded sHLA-G (cut-off at 128U/ml) plus CA125 in two-biomarker panel test and CA125 plus CA199 plus sHLA-G or CA125 plus CA724 plus sHLA-G in three-biomarker panel test were better choices for GC discrimination. Our findings indicated that sHLA-G was a potential biomarker for GC diagnosis and the combination of sHLA-G with CA125, CA19-9 and CA72-4 can improve the clinical screening and diagnosis for GC.

1688 related Products with: Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer.

Human Gastrointestinal Ca Growth Differentiation Fa Mouse Anti-Human CA19-9 ( Blood Group Antibodies a anti B human blood group serologically defined col Glycosylated Soluble LOX Human enzymes and protein Rabbit Anti-GAGE7 Cancer Mouse Anti-Human Guanylat Mouse Anti-Human Leukocyt Mouse Anti-Human Guanylat

Related Pathways

paperclip

#26318783   // Save this To Up

Metal ions doped chitosan-poly(acrylic acid) nanospheres: Synthesis and their application in simultaneously electrochemical detection of four markers of pancreatic cancer.

In this work, a one-pot method was designed to synthesize copper ions, cadmium ions, lead ions and zinc ions doped chitosan-poly(acrylic acid) nanospheres. Those nanospheres can not only produce independent electrochemical signals, but also react with glutaraldehyde (GA) to immobilize different labeled antibodies. Using the modified nanospheres as immunoprobes, a sandwich-type immunosensor was fabricated to simultaneous detection of four tumor markers (CEA, CA199, CA125 and CA242) of pancreatic cancer. This designed immunosensor exhibited good linear relationships in range from 0.1 to 100ng mL(-1) for CEA, 1 to 150UmL(-1) for CA199, CA125 and CA242, corresponding detection limits 0.02ng mL(-1), 0.4UmL(-1), 0.3UmL(-1) and 0.4UmL(-1), respectively. Meanwhile, the immunosensor was applied in analysis of clinical serum samples, whose results were well agreed with the enzyme-linked immunosorbent assay (ELISA), indicating that the proposed immunosensor gave a hope for the identification and validation of specific early cancer.

2650 related Products with: Metal ions doped chitosan-poly(acrylic acid) nanospheres: Synthesis and their application in simultaneously electrochemical detection of four markers of pancreatic cancer.

Breast cancer tissue arra Rabbit Anti-IAA (Indole-3 Rabbit Anti-IAA (Indole-3 trans Indole 3 acrylic ac Mid advanced stage pancre Pancreatic disease spectr High density pancreatic c Pancreatic cancer tissue Multiple pancreatic cance Pancreatic cancer and nor Pancreatic cancer tissue Pancreatic cancer and nor

Related Pathways

paperclip

#25556459   // Save this To Up

Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.

To evaluate the value of combined detection of serum CEA, CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS for the clinical diagnosis of upper gastrointestinal tract (GIT) cancer and to analyze the efficacy of these tumor markers (TMs) in evaluating curative effects and prognosis. A total of 573 patients with upper GIT cancer between January 2004 and December 2007 were enrolled in this study. Serum levels of CEA, CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS were examined preoperatively and every 3 months postoperatively by ELISA. The sensitivity of CEA, CA19-9, CA24-2, AFP, CA72-4, SCC, TPA and TPS were 26.8%, 36.2%, 42.9%, 2.84%, 25.4%, 34.6%, 34.2% and 30.9%, respectively. The combined detection of CEA+CA199+CA242+CA724 had higher sensitivity and specificity in gastric cancer (GC) and cardiac cancer, while CEA+CA199+CA242+SCC was the best combination of diagnosis for esophageal cancer (EC). Elevation of preoperative CEA, CA19-9 and CA24-2, SCC and CA72-4 was significantly associated with pathological types (p<0.05) and TNM staging (p<0.05). Correlation analysis showed that CA24-2 was significantly correlated with CA19-9 (r=0.810, p<0.001). The levels of CEA, CA19-9, CA24-2, CA72-4 and SCC decreased obviously 3 months after operations. When metastasis and recurrence occurred, the levels of TMs significantly increased. On multivariate analysis, high preoperative CA72-4, CA24-2 and SCC served as prognostic factors for cardiac carcinoma, GC and EC, respectively. combined detection of CEA+CA199+CA242+SCC proved to be the most economic and practical strategy in diagnosis of EC; CEA+CA199+CA242+CA724 proved to be a better evaluation indicator for cardiac cancer and GC. CEA and CA19-9, CA24-2, CA72-4 and SCC, examined postoperatively during follow-up, were useful to find early tumor recurrence and metastasis, and evaluate prognosis. AFP, TPA and TPS have no significant value in diagnosis of patients with upper GIT cancer.

1260 related Products with: Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.

Breast cancer tissue arra Multiple organ gastrointe Liver cancer tissue array Interstitialoma of gastro Mouse Anti-Human CA19-9 ( PSA test card, serum , Ca Fecal Occult Blood test s Cancer Markers CA 19 9 96 Cancer Apoptosis Phospho- (7’-Benzyloxy-indolymet Top five cancer tissue ar Multiple organs tumor and

Related Pathways

paperclip

#25119103   // Save this To Up

The effects of PTBP3 silencing on the proliferation and differentiation of MKN45 human gastric cancer cells.

PTBP3 overexpression inhibits the differentiation of leukemia cells; however, its effects on the differentiation and proliferation of solid cancer cells remain unclear. Thus, the impact of PTBP3 on the differentiation and proliferation of gastric cancer cells was investigated.

1616 related Products with: The effects of PTBP3 silencing on the proliferation and differentiation of MKN45 human gastric cancer cells.

Epidermal Growth Factor ( Epidermal Growth Factor ( TCP-1 theta antibody Sour Recombinant Human PKC the Recombinant Human PKC the Recombinant Human PKC the Multiple organ cancer tis Anti C Reactive Protein A Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon Growth Differentiation Fa Growth Differentiation Fa

Related Pathways

paperclip

#25090262   // Save this To Up

Predictive value of cystic fibrosis transmembrane conductance regulator (CFTR) in the diagnosis of gastric cancer.

Gastric cancer is associated with poor prognosis. The high mortality rate of gastric cancer is mainly attributed to late detection, so diagnosis and treatment are crucial to decreasing mortality. The purpose of this study was to examine the predictive accuracy and discriminative ability of cystic fibrosis transmembrane conductance regulator (CFTR) in gastric cancer patients, in addition to the classical cancer tumor biomarkers carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA).

2140 related Products with: Predictive value of cystic fibrosis transmembrane conductance regulator (CFTR) in the diagnosis of gastric cancer.

GI cancer (esophageal, ga Cancer Apoptosis Phospho- Top five cancer tissue ar Tissue array of gastric d Multiple organ cancer tis Lung cancer tissue array, Lung cancer tissue array Colon cancer and normal t Colon cancer and normal t Colon cancer, metastasize Colon cancer and matched Colon cancer tissue array

Related Pathways

paperclip

#24697115   // Save this To Up

Clinical significance of combined testing of YKL-40 with CEA in Chinese colorectal cancer patients.

To investigate the practical value of individual and combined testing of plasma levels of YKL-40, CEA, and CA199 for auxiliary diagnosis and detection of recurrence of colorectal cancer.

2467 related Products with: Clinical significance of combined testing of YKL-40 with CEA in Chinese colorectal cancer patients.

Multiple organ cancer tis Lung cancer tissue array Colon cancer and normal t Colon cancer and normal t Colon cancer, metastasize Colon cancer and matched Colon cancer tissue array Kidney cancer tissue arra Ovary cancer tissue array Bladder cancer tissue arr Prostate cancer, adjacent Bladder cancer tissue arr

Related Pathways